Old Web
English
Sign In
Acemap
>
authorDetail
>
Cristina Karen Rodriguez Lorenc
Cristina Karen Rodriguez Lorenc
Novartis
Oncology
Internal medicine
Medicine
Cancer
Breast cancer
2
Papers
20
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (2)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Phase 1b Dose Escalation/Expansion Trial of Ribociclib in Combination With Everolimus and Exemestane in Postmenopausal Women With HR+, HER2- Advanced Breast Cancer.
2020
Clinical Cancer Research
Aditya Bardia
Shanu Modi
Mafalda Oliveira
Javier Cortes
Mario Campone
Brigette B.Y. Ma
Luc Dirix
Amy Weise
Becker Hewes
Ivan Diaz-Padilla
Yu Han
Priya Deshpande
Tanay S. Samant
Cristina Karen Rodriguez Lorenc
Wei He
Fei Su
Mariana Chavez-MacGregor
Show All
Source
Cite
Save
Citations (4)
Ribociclib (RIB) + fulvestrant (FUL) in postmenopausal women with hormone receptor-positive (HR+), HER2-negative (HER2–) advanced breast cancer (ABC): Results from MONALEESA-3.
2018
Journal of Clinical Oncology
Dennis J. Slamon
Patrick Neven
Stephen Chia
Seock-Ah Im
Peter A. Fasching
Michelino DeLaurentiis
Katarína Petráková
Giulia Valeria Bianchi
Francisco J. Esteva
Miguel Martín
Xavier Pivot
Gena Vidam
Yingbo Wang
Cristina Karen Rodriguez Lorenc
M Miller
Tanya Taran
Guy Jerusalem
Show All
Source
Cite
Save
Citations (16)
1